PaxMedica's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means PaxMedica's Accounts Receivable
stayed the same
from Dec. 2023 to Mar. 2024 .
PaxMedica's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means PaxMedica's Accounts Receivable
stayed the same
from Dec. 2022 to Dec. 2023 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PaxMedica's liquidation value for the
three
months ended in Mar. 2024 was $-0.08 Mil.
PaxMedica Change In Receivables Historical Data
The historical data trend for PaxMedica's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PaxMedica (OTCPK:PXMD) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PaxMedica's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PaxMedica Change In Receivables Related Terms
Thank you for viewing the detailed overview of PaxMedica's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PXMD has been successfully added to your 